← Eichor
Study identifier: NCT05737342 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose

Condition: High Blood Sugar · Metabolic Syndrome  ·  Sponsor: SunWay Biotech Co., LTD.

PhaseNA
Planned participants80
Who can joinAll sexes, 20 Years to no upper limit
Healthy volunteersNo

About this study

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

This description comes directly from the study's public registry record.

Talk to the study team

Sean Lin  ·  02-27929568  ·  sean.lin@sunway.cc

Always discuss trial participation with your own doctor first.

Locations (1)

Tri-Service General Hospital, National Defense Medical Center, Taipei city,Taipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05737342